WVE WAVE Life Sciences

WAVE Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be presenting at the following upcoming investor conferences:

  • Leerink Partners Global Healthcare Conference 2017

    Wednesday, February 15th at 1:30 P.M. ET – New York
  • RBC Capital Markets 2017 Healthcare Conference

    Thursday, February 23rd at 2:05 P.M. ET – New York

A live webcast of each presentation will also be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. After each webcast, a replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

EN
06/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

 PRESS RELEASE

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results...

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events”...

 PRESS RELEASE

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement...

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 Data from the 400 mg multidose cohort of RestorAATion-2 clinical...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch